COSMO BIO COMPANY,LIMITED
3386・Standard Market・Wholesale Trade
Governance
A company with an Audit and Supervisory Committee. The Board of Directors consists of 7 members (including 4 outside directors, all of whom are independent outside directors and members of the Audit and Supervisory Committee), giving an outside director ratio of approximately 57%. No nomination committee or compensation committee has been established. Effective April 1, 2026, the company plans to newly establish an Executive Officer Committee and a Risk and Compliance Committee to strengthen the separation of oversight and business execution.
Risk Management
The company has established a "Risk Management Committee" (comprising full-time officers, executive officers, and department/division heads), chaired by the Representative Director and President, to promote organizational risk management. Important matters are to be submitted to the Board of Directors. Effective April 1, 2026, the committee is scheduled to be integrated with the Corporate Ethics Committee and reorganized as the "Risk & Compliance Committee." The Audit Office, under the direct authority of the Representative Director and President, conducts internal audits and reports the results to the Board of Directors and the Audit and Supervisory Committee.
Shareholder Returns
Basic policy of stable dividends, determined with emphasis on the payout ratio and DOE. The annual dividend for FY2025 (ending December 2025) is ¥50 per share (interim ¥25, year-end ¥25). The same annual amount of ¥50 (interim ¥25, year-end ¥25) is forecast for FY2026 (ending December 2026). Share buybacks can be implemented by board of directors resolution under the Articles of Incorporation.
Dividend Policy
Dividends are determined with stable dividends in mind, placing emphasis on the payout ratio and DOE (dividend on equity ratio), while comprehensively taking into account the outlook for earnings and other factors. The basic policy is to pay dividends twice a year, as an interim dividend and a year-end dividend. The actual result for FY2025 (ending December 2025) was ¥50 per share annually (interim ¥25, year-end ¥25). The forecast for FY2026 (ending December 2026) remains unchanged at ¥50 per share annually (interim ¥25, year-end ¥25).
ESG
Materiality in E, S, and G has been identified based on the core theme of "contributing to the advancement of life sciences." On the environmental side, the company is promoting waste and wastewater management, the introduction of eco-friendly materials, and improved logistics efficiency. In terms of human capital, the company has achieved a 54% female employee ratio and a 39% female management ratio, while utilizing telework and flextime systems as well as engagement surveys. No disclosure of quantitative targets related to climate change has been confirmed at this time.
Last updated: March 18, 2026